Jason Coarse

Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-α inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE)

Joseph F. Merola, Robert Landewé, Iain B. McInnes et al. · The Lancet · 2022 · 158 citations · Full text

Medicine, Immunology, Pharmacotherapy +16

Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: a randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL)

Iain B. McInnes, Akihiko Asahina, Laura C. Coates et al. · The Lancet · 2022 · 157 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Bimekizumab in patients with active psoriatic arthritis: results from a 48-week, randomised, double-blind, placebo-controlled, dose-ranging phase 2b trial

Arthur Kavanaugh, Joseph F. Merola, Georg Schett et al. · The Lancet · 2020 · 142 citations · Full text

Medicine, Clinical Sciences, Pharmacotherapy +8

Dual neutralisation of interleukin-17A and interleukin-17F with bimekizumab in patients with active ankylosing spondylitis: results from a 48-week phase IIb, randomised, double-blind, placebo-controlled, dose-ranging study

Désirée van der Heijde, Lianne S. Gensler, Atul Deodhar et al. · Annals of the Rheumatic Diseases · 2020 · 130 citations · Full text

Medicine, Immunology, Pharmacotherapy +16

Exposure‐response relationship of certolizumab pegol induction and maintenance therapy in patients with Crohn's disease

Niels Vande Casteele, Brian G. Feagan, Séverine Vermeire et al. · Alimentary Pharmacology & Therapeutics · 2017 · 46 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17